Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review

Primer Autor
Sandoval, Cristian
Co-autores
Reyes, Carolina
Rosas, Pamela
Godoy, Karina
Souza-Mello, Vanessa
Farias, Jorge
Título
Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review
Editorial
MDPI
Revista
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Lenguaje
en
Resumen
Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of liver abnormalities, from benign steatosis to nonalcoholic steatohepatitis (NASH). Because of their antioxidant capabilities, CeNPs have sparked a lot of interest in biological applications. This review evaluated the effectiveness of CeNPs in NAFLD evolution through in vivo and in vitro studies. Databases such as MEDLINE, EMBASE, Scopus, and Web of Science were looked for studies published between 2012 and June 2023. Quality was evaluated using PRISMA guidelines. We looked at a total of nine primary studies in English carried out using healthy participants or HepG2 or LX2 cells. Quantitative data such as blood chemical markers, lipid peroxidation, and oxidative status were obtained from the studies. Our findings indicate that NPs are a possible option to make medications safer and more effective. In fact, CeNPs have been demonstrated to decrease total saturated fatty acids and foam cell production (steatosis), reactive oxygen species production and TNF-alpha (necrosis), and vacuolization in hepatic tissue when used to treat NAFLD. Thus, CeNP treatment may be considered promising for liver illnesses. However, limitations such as the variation in durations between studies and the utilization of diverse models to elucidate the etiology of NAFLD must be considered. Future studies must include standardized NAFLD models.
Fecha Publicación
2023
Tipo de Recurso
artículo de revisión
doi
10.3390/ijms242115728
Formato Recurso
PDF
Palabras Claves
drug delivery system
liver disease
nanoceria
therapy
Ubicación del archivo
http://dx.doi.org/10.3390/ijms242115728
Categoría OCDE
Bioquímica y biología molecular
Química
Materias
sistema de suministro de medicamento
enfermedad del higado
nanoceria
terapia
Identificador del recurso (Mandatado-único)
artículo de revisión
Versión del recurso (Recomendado-único)
versión publicada
License
CC BY 4.0
Condición de la licencia (Recomendado-repetible)
CC BY 4.0
Derechos de acceso
acceso abierto
Access Rights
acceso abierto
Id de Web of Science
WOS:001100204200001
ISSN
1661-6596
Tipo de ruta
verde# dorado
Categoría WOS
Bioquímica y biología molecular
Química
Referencia del Financiador (Mandatado si es aplicable-repetible)
ANID CCSS210005
UFRO PDT22-0001
UFRO DI22-0007
Colecciones
Colección Publicaciones Científicas
Colección ANID
Revisa las metricas alternativas de Almetrics
Revisa las citaciones de Dimensions